We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bayer Sues Chiron Over Diagnostic Acquisition

By HospiMedica staff writers
Posted on 11 Feb 2002
Print article
A lawsuit has been filed in a US federal court by a US subsidiary of Bayer Corp. (Leverkusen, Germany) against biotechnology company Chiron Corp. (Emeryville, CA, USA) over Bayer's acquisition of the Chiron Diagnostics Corp. for more than US$1 billion in 1998. The products of Chiron Diagnostics included blood tests and analyzers used in critical care. Following the acquisition, the unit became part of Bayer Diagnostics.

The suit contends that Chiron did not disclose regulatory, patent, and equipment problems to Bayer prior to the acquisition. Bayer also says that the Rapidpoint 400 blood analyzer of Chiron, launched shortly before the acquisition, gave false readings, had not been tested properly, and did not meet US Food and Drug Administration (FDA) standards. In addition, Bayer claims that Chiron did not provide details that should have been provided to the company about Japanese-employee pension liabilities, a patent license, and suspected violations of Mexican law. Chiron has not commented as yet on the suit.




Related Links:
Chiron
Bayer
Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The breakthrough could result in a higher success rate using a simple oral swab test before IVF (Photo courtesy of Shutterstock)

POC Oral Swab Test to Increase Chances of Pregnancy in IVF

Approximately 15% of couples of reproductive age experience involuntary childlessness. A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more